Objective To describe the efficacy and safety of biologics for the treatment of eosinophilic
granulomatosis with polyangiitis (EGPA). Methods A retrospective European collaborative …

Objective We investigated the effectiveness of rituximab (an anti-CD20 monoclonal
antibody) in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Methods We …

Background Eosinophilic granulomatosis with polyangiitis is an eosinophilic vasculitis.
Mepolizumab, an anti–interleukin-5 monoclonal antibody, reduces blood eosinophil counts …

Eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome) is a rare
type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic …

Objective Mepolizumab proved to be an efficacious treatment for eosinophilic
granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the …

Therapeutic advances in eosinophilic granulomatosis with pol... : Current Opinion in
Rheumatology Therapeutic advances in eosinophilic granulomatosis with polyangiitis …

Objective To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with
polyangiitis (EGPA) with and without a vasculitic phenotype. Methods The MIRRA study …

Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of
antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct …

Objective. To systematically evaluate, through a Medline search, the role of omalizumab in
eosinophilic granulomatosis with polyangiitis (EGPA). Methods. A systematic review was …

Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis
characterized by asthma, systemic manifestations, and blood and tissue eosinophilia …